AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01856972 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rearfoot joint mobilization
Description: A high velocity-low amplitude distractive thrust is directed at the talocrural joint. The procedure is performed with the patient in the supine position. The therapist interlaces hands over the dorsum of the foot with 5th digit placed on talus. The therapist slightly pronates and dorsiflexes the foot. Tension is taken up in a caudal direction until the soft tissue barrier is engaged. A distractive thrust is then applied. This is performed up to 2 times. If the therapist notes a cavitation, the patient is progressed to ROM exercises. If there is no cavitation is noted by the therapist the thrust mobilization is reapplied.
Study NCT01856972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static stretching/ROM exercises
Description: Gastrocnemius stretch at wall 3 sets of 30 second holds. Soleus stretch at wall 3 sets of 30 second holds. Standing bilateral dorsiflexion on step x30 with full ROM. Standing bilateral plantar flexion on step x30 with full ROM.
Study NCT01856972 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static stretching/ROM exercises
Description: Gastrocnemius stretch at wall 3 sets of 30 second holds. Soleus stretch at wall 3 sets of 30 second holds. Standing bilateral dorsiflexion on step x30 with full ROM. Standing bilateral plantar flexion on step x30 with full ROM.
Study NCT04007536 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study NCT01159067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deferasirox
Description: Given orally
Study NCT00458016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB07803
Description: Daily oral administration
Study NCT00458016 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral administration
Study NCT02441959 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar discectomy Open
Description: Open Discectomy
Study NCT02681874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SSC Program
Description: The Smart and Secure Children (SSC) program is a 10-week manualized intervention that uses a written validated curriculum. The program is group-based and co-led by peer leaders (Parent Leaders). Parent Leaders facilitate conversations on the SSC program content by sharing real life application, experiences, and solutions.
Study NCT02681874 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written Handouts
Description: The handouts are a part of the SSC program that include didactic curriculum content and instruct parents to write goals and document goal progress.
Study NCT02340559 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meta-cognitive Training
Study NCT02340559 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational group
Study NCT01849341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast alternated days
Description: 500 mcg per day on alternate days (roflumilast 500μg eod) for 2 weeks
Study NCT01849341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast 500 mcg per day
Study NCT03076840 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio tape
Description: Kinesio Taping is another option for the treatment of poor hamstring extensibility, It was developed by Kenzo Kase in 1970 and gained a wide popularity by the elite athletes during the various championships and Olympic Games
Study NCT03076840 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Kinesio tape
Description: Kinesio Taping is another option for the treatment of poor hamstring extensibility, It was developed by Kenzo Kase in 1970 and gained a wide popularity by the elite athletes during the various championships and Olympic Games
Study NCT01522859 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telehealth monitoring system (Honni Med)
Description: The system is uploaded with personal information including: monitoring start time; clinical observations (blood pressure, heart rate, oxygen saturations); and questions relating to symptoms. The patient is instructed on use and observed monitoring. The patient is monitored daily for a period of six months. The monitoring session lasts approximately 10 minutes during which the patient attaches a finger probe and blood pressure cuff and responds 'yes' or 'no' to the set questions. Daily data is transmitted via a phone line to a secure server to be downloaded and reviewed by a Telehealth nurse.If one or more of the clinical observations is outside normal limits the appropriate healthcare intervention is utilised.
Study NCT02811198 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT02172313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: For oral administration.
Study NCT01259193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib and Zoledronic Acid
Description: Sorafenib ,tablet,400mg Bid ,until patient can not tolerance Zoledronic Acid ,powder for injection,4mg per 3 week for 1 year
Study NCT01067079 — intervention group
Intervention type: OTHER
Intervention: No vaccine administered; subjects only have blood sampling for immunogenicity
Description: No vaccine administered; subjects only have blood sampling for
Study NCT02264834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine 0.1% + Sufentanil 0.2µg/ml
Description: Levobupivacaine 0.1% + Sufentanil 0.2µg/ml
Study NCT02264834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.07% + Sufentanil 0.3µg/ml
Description: Levobupivacaine 0.07% + Sufentanil 0.3µg/ml
Study NCT02264834 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar epidural analgesia
Description: Introduction of a catheter in lumbar epidural space
Study NCT02264834 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar epidural analgesia
Description: Introduction of a catheter in lumbar epidural space
Study NCT00322062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate
Description: 2L gut lavage solution
Study NCT00322062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Phosphate Solution
Description: 1 x 45ml solution, BID
Study NCT01696032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGI-110
Study NCT01696032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment of Choice (topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine)
Description: Investigator chose to treat with either topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine
Study NCT01696032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT04972435 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Contrast sensitivity
Description: All subjects performed the contrast sensitivity measurement preoperatively and one time at 2 months postoperatively.
Study NCT04972435 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast sensitivity
Description: All subjects performed the contrast sensitivity measurement preoperatively and one time at 2 months postoperatively.
Study NCT02515162 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fischer Cone Biopsy Excisor
Description: Electrosurgical excision method using a triangular electrode to remove the abnormal cervical Transformation zone
Study NCT02441959 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lumbar discectomy Open
Description: Open Discectomy
Study NCT02441959 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar discectomy Endoscopic
Description: Endoscopic Discectomy
Study NCT03273010 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free gingival graft
Description: Free gingival graft was harvested from palatal donor site
Study NCT03273010 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Free gingival graft
Description: Free gingival graft was harvested from palatal donor site
Study NCT03273010 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate application
Description: Periacyrl was applied on palatal wounds
Study NCT01307488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir boosted Atazanavir + Lamivudine
Description: ATV/RTV 300/100 mg QD + 2 optimized NRTIs for the first 4 weeks and then they will receive ATV/RTV 300/100 mg QD (once daily) and 3TC 300 mg QD for another 92 weeks. Treatment should be taken orally with a light meal at the same time each day.
Study NCT01307488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir boosted Atazanavir + 2 NRTIs
Description: ATV/RTV 300/100 mg QD + 2 optimized NRTIs for 96 weeks. Treatment should be taken orally with a light meal at the same time each day.
Study NCT02687763 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ProQuad
Description: 2) Patients 6 months to 24 months of age who are being considered and/or evaluated for any solid organ transplant within the next five (5) years who are willing:~1. to receive two doses of ProQuad® at least 30 days but no more than 365 days apart.~2. to participate in the three (3) antibody titer blood draws.
Study NCT01179256 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CURCUMIN
Description: oral supplementation of curcumin 2000mg
Study NCT01179256 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no intervention other than stopping study
Description: no intervention other than stopping study
Study NCT00500656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icatibant
Description: Icatibant: a stable, synthetic decapeptide and specific BK B2 receptor antagonist.
Study NCT00500656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: over encapsulated film tablet an anti-fibrinolytic agent,is used in some European countries for the treatment of acute oedema episodes and the continuous prophylaxis of HAE.
Study NCT00500656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: hard capsule matched to tranexamic acid
Study NCT00500656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S.C. Placebo
Description: solution for injection, matched to icatibant for injection
Study NCT02233465 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IPOM Mesh-repair parastomal hernia
Description: Safety study for mesh-repair of parastomal hernia
Study NCT02953418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: RFA
Study NCT03640442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified ramped position
Description: This position will be achieved using a special pillow. Shoulders will be elevated and neck will be extended to bring the breasts away from the laryngoscopy. The patient will be positioned so that the tip of the last spinous process (C7) will be at the edge of the pillow. The neck will be extended to the most possible range.
Study NCT03640442 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ramped position
Description: This position will be achieved by elevation of the shoulders and the head elevation till achieving alignment of sternal notch and external auditory meatus
Study NCT01279265 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutramigen with Enflora
Description: Hypoallergenic formula with probiotic - Lactobacillus GG
Study NCT01279265 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nutramigen A+
Description: Hypoallergenic formula without lactobacillus
Study NCT02264509 — intervention group
Intervention type: PROCEDURE
Intervention: Ankle-Brachial index
Description: The only procedure to be performed is the measurement of ABI for the diagnosis of arterial insufficiency.
Study NCT02603536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WelTel
Description: An evidence-based, text messaging solution for improving patient adherence.
Study NCT03083639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole Capsule
Description: Esomeprazole Capsule
Study NCT03083639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole Tablet
Description: Esomeprazole Tablet
Study NCT00713765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3480
Description: 18 total doses of 40 mg, on days 1-18
Study NCT00713765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: One single dose of mg on day 5
Study NCT02449109 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interventional therapy
Description: Liver cancer patients received drug interventional therapy using the digital subtraction angiography（DSA）
Study NCT02449109 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interventional therapy
Description: Liver cancer patients received drug interventional therapy using the digital subtraction angiography（DSA）
Study NCT01596049 — intervention group
Intervention type: DEVICE
Intervention: Self-fixating Mesh
Description: Using Self-fixating Mesh for Inguinal Hernia Repair
Study NCT04269746 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CCAT1
Description: Long Non coding RNA
Study NCT04650984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onfekafusp alfa
Description: Patients will receive a fixed dose of L19TNF in combination with a fixed dose of doxorubicin.
Study NCT04650984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Patients will receive a fixed dose doxorubicin, administered as a 15 ± 5 minutes i.v. infusion.
Study NCT04650984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Patients will receive a fixed dose doxorubicin, administered as a 15 ± 5 minutes i.v. infusion.
Study NCT04375735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bovine Lipid Extract Surfactant
Description: BLES will be administered in doses of 50mg/kg ideal bodyweight, at a concentration of 27mg/ml so a total volume of approximately 2ml/kg will be administered. The material will be instilled via the suction catheter through the ET tube so that the ventilation circuit is not broken. Half of the material will be instilled with the patient positioned on their left and right sides, with a pause to allow 5 min of MV between. The procedure will be repeated at, 24 and 48 hours while intubated, so the patient will receive up to 3 doses. To minimize aerosol generation, all patients will be paralyzed during surfactant administration and the ventilator will be paused. The proposed administration technique, surfactant concentration, volume and dosing schedule is based on previous studies, and has shown to be safe in patients with ARDS.
Study NCT04049448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464
Description: All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 2 years (104 weeks).
Study NCT03016988 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bortezomib
Description: Bortezomib(V) 1.3mg/m2, subcutaneously,day 1,4,8,11;
Study NCT03016988 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine
Description: Fludarabine(F) 25mg/m2, intravenously day 1-3;
Study NCT03016988 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cytarabine
Description: Cytarabine(A) 500mg/m2 for 3 days(day1-3)
Study NCT03671135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TCA Intrastromal Inlay
Description: Anterior surface of Bowmans Layer Corneal Optical Correction Inlay
Study NCT01845181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-680
Description: Dose: 10, 20, 40 ,60 mg/day (making combination of 5 y 20 mg forms).
Study NCT01845181 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 or 2 or 3 capsules of placebo.
Study NCT04241068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aducanumab
Description: Administered as specified in the treatment arm.
Study NCT01905007 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Defibrillation testing
Description: Defibrillation testing at initial ICD implantation
Study NCT01636258 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Every other week
Study NCT01636258 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Every week
Study NCT03469440 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous central venous oxygenation monitoring
Description: Central venous oxygen saturation will be targeted higher than 65% in non-cyanogenic patients and 55% in cyanogenic.~* First, isotonic crystalloid, 10 up to 20 mL/kg, will be administered in boluses to achieve continuous central venous oxygen saturation higher than 65% in non-cyanogenic and 55% in cyanogenic.~* Second, if not achieved with fluid administration, will be targeted by initiating and titrating inotropics (dobutamine or milrinone). If the mean arterial pressure is lower than 50 mm Hg will be associated epinephrine.~* If the ScvO2 is lower than 65% in non-cyanogenic and 55% in cyanogenic and the hemoglobin was lower than 8g/dl, red blood cells (20mL/Kg) will be transfused to achieve a hemoglobin level of at least 8g/dL.
Study NCT03469440 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard protocol
Description: The control group will keep the standard therapy to achieve mean arterial pressure higher than 50mmHg, central venous pressure 8 to 12 mmHg, urinay debit higher than 0,5ml/kg/h, hemoglobin higher or equal than 8g/dL, arterial oxygen saturation higher or equal than 92% in non-cyanogenic and 80% cyanogenic, central venous oxygen saturation higher or equal than 65% in non-cyanogenic and 55% in cyanogenic.
Study NCT03046966 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intervention: Receives Training
Description: • Complete a Hands-on Intubation in the Simulation Lab with PI instructing:~* Using state of the art technology, a Storz C-MAC video laryngoscope~* Identifying anatomical landmarks~* Practice on the manikin until intubation occurs within 15 seconds
Study NCT03046966 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intervention: Control No Training
Description: • Does not receive simulation training with PI. Only standard training.
Study NCT02515162 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Loop Excision Procedure
Description: Electrosurgical excision method using a circular electrode to remove the abnormal cervical Transformation zone
Study NCT05801627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAL067
Description: SAL067 6mg(2 tablet) and Metformin ≥1500mg
Study NCT05801627 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (2 tablet) and Metformin ≥1500mg
Study NCT03099135 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: No Treatment
Description: No treatment will be given tp participants during this follow-up study of previous phase II and Phase III in which they have received Odalavir and AL-335 with or without Simeprevir.
Study NCT02311049 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionation
Study NCT03724825 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: lipid profile: Total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL) and high density lipoprotein (HDL))
Description: blood samples will be collected after 10 hours fasting
Study NCT03724825 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Total testosterone
Description: blood samples will be collected after 10 hours fasting
Study NCT03724825 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Adropin
Description: blood samples will be collected after 10 hours fasting
Study NCT03724825 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Adiponectin
Description: blood samples will be collected after 10 hours fasting
Study NCT01438190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin, gonadotropins in step-down regimen
Description: Metformin 850 mg cps, two cps daily for 12 weeks. gonadotropins 75IU f, step-down regimen, starting dose of 225 IU daily.
Study NCT01438190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo, gonadotropins in step-up regimen
Description: Placebo cps, two cps daily. Gonadotropins 75IU f, step-up regimen, starting dose of 75 IU daily.
Study NCT01915368 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stroke Management Program (SMP)
Description: Participants will have usual care, and in addition, be provided with periodic information about their progress in the area of mobility using specialized activity monitors
Study NCT01915368 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stroke Monitoring Program (SMonP)
Description: Participants will have usual care, and in addition, be progressed according to customized protocols using feedback from specialized activity monitors
Study NCT01915368 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stroke Supplementary Program (SSP)
Description: Participants will have usual care, and in addition, will receive the same as the Stroke Monitoring Group, and also receive one additional hour of daily (5 times per week) physical exercise
Study NCT01196728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM3.1-AC100
Description: SAD study with single ascending subcutaneous doses